The Experts below are selected from a list of 48060 Experts worldwide ranked by ideXlab platform
N.christopher Kelley - One of the best experts on this subject based on the ideXlab platform.
-
The risk of upper Gastrointestinal Cancer in familial adenomatous polyposis.
Gastroenterology, 1992Co-Authors: G. Johan A. Offerhaus, Susan V. Booker, Anne C. Tersmette, N.christopher KelleyAbstract:Abstract Adenomas with potential for malignancy occur frequently in the upper Gastrointestinal tract of patients with familial adenomatous polyposis. However, an assessment of relative risk of upper Gastrointestinal Cancer in patients with adenomatous polyposis has never been performed. Therefore, the incidence rate of upper Gastrointestinal Cancer in patients with familial adenomatous polyposis in The Johns Hopkins Registry was compared with the rate of the general population through person-year analysis with adjustment for demographics. There was an increased relative risk of duodenal adenocarcinoma (relative risk, 330.82; 95% confidence limits, 132.66 and 681.49; P P
G. Johan A. Offerhaus - One of the best experts on this subject based on the ideXlab platform.
-
The risk of upper Gastrointestinal Cancer in familial adenomatous polyposis.
Gastroenterology, 1992Co-Authors: G. Johan A. Offerhaus, Susan V. Booker, Anne C. Tersmette, N.christopher KelleyAbstract:Abstract Adenomas with potential for malignancy occur frequently in the upper Gastrointestinal tract of patients with familial adenomatous polyposis. However, an assessment of relative risk of upper Gastrointestinal Cancer in patients with adenomatous polyposis has never been performed. Therefore, the incidence rate of upper Gastrointestinal Cancer in patients with familial adenomatous polyposis in The Johns Hopkins Registry was compared with the rate of the general population through person-year analysis with adjustment for demographics. There was an increased relative risk of duodenal adenocarcinoma (relative risk, 330.82; 95% confidence limits, 132.66 and 681.49; P P
Bao Guo-qian - One of the best experts on this subject based on the ideXlab platform.
-
Progress in the relation of NO and Gastrointestinal Cancer.
Journal of Modern Oncology, 2005Co-Authors: Bao Guo-qianAbstract:Accumulating evidence indicates that NO pathway play a patent role in the Gastrointestinal carcinogenesis. NO pathway is involved in immune responses, DNA damage, regulation of apoptosis. NO, which is generated under chronic inflammatory conditions that predispose individuals to Cancer, has paradoxical effects. On the other hand, NO enhance tumor angiogenesis and to induce vasodilatation, thus accelerates tumor growth. But the role of NO in Gastrointestinal Cancer remains controversial, and iNOS has been reported to be up regulated and down regulated in Gastrointestinal Cancer. The review is based on the resent studies about the effects of NO pathway to Gastrointestinal Cancer.
Yifeng Cheng - One of the best experts on this subject based on the ideXlab platform.
-
correlation of dapk1 methylation and the risk of Gastrointestinal Cancer a systematic review and meta analysis
PLOS ONE, 2017Co-Authors: Wenzheng Yuan, Jintong Ji, Jinhuang Chen, Zili Zhou, Yifeng Cheng, Liang Wu, Qiang Tang, Bin JiangAbstract:Objective One of the critical mechanisms of Gastrointestinal Cancer pathogenesis is the silencing of death associated protein kinase 1 (DAPK1), which could be caused by aberrant methylation of the promoter. However, the relationship between DAPK1 methylation and the risk of Gastrointestinal Cancer is still controversial. Hence, we conducted this study to determine the potential correlation. Methods Eligible publications were searched in the Pubmed, Embase, and Cochrane Library through November 2016 according to the inclusion criteria and exclusion criteria. Revman 5.3 and Stata 12.0 software were used to analyze the relevant data regarding the association between the frequency of DAPK1 methylation and Gastrointestinal Cancer. Results A total of 22 studies with 2406 patients were included in this meta analysis. Methylation of DAPK1 was positively related with the risk of Gastrointestinal Cancer (odds ratio [OR] = 5.35, 95% confidence interval [CI]: 2.76–10.38, P<0.00001, random effects model). The source of heterogeneity was analyzed by sensitivity analysis and subgroup analysis. After omitting one heterogeneous study, the I2 decreased and the OR increased in pooled analysis. Also, the heterogeneity decreased most significantly in the subgroup of studies that had a sample size of less than 60 cases. Then, the correlations between DAPK1 methylation and clinicopathological features of Gastrointestinal Cancer were assessed. DAPK1 methylation was positively correlated with the lymph node (N) stage (positive vs. negative, OR = 1.45, 95%CI: 1.01–2.06, P = 0.04, fixed effects model) and poor differentiation (OR = 1.55, 95%CI: 1.02–2.35, P = 0.04, fixed effects model) in gastric Cancer, and the association was significant among Asian patients. However, among cases of Gastrointestinal Cancer, the association between DAPK1 methylation and tumor (T) stage, N stage, distant metastasis (M) stage, and Cancer differentiation were not statistically significant. Conclusions DAPK1 methylation is a potential biomarker for the early diagnosis of Gastrointestinal Cancer. Further analysis of the clinicopathological features indicated that aberrant methylation of DAPK1 is positively associated with the tumorigenesis of Gastrointestinal Cancer, and metastasis of gastric Cancer.
-
Correlation of DAPK1 methylation and the risk of Gastrointestinal Cancer: A systematic review and meta-analysis.
PLOS ONE, 2017Co-Authors: Wenzheng Yuan, Jintong Ji, Jinhuang Chen, Zili Zhou, Liang Wu, Qiang Tang, Yifeng ChengAbstract:Objective One of the critical mechanisms of Gastrointestinal Cancer pathogenesis is the silencing of death associated protein kinase 1 (DAPK1), which could be caused by aberrant methylation of the promoter. However, the relationship between DAPK1 methylation and the risk of Gastrointestinal Cancer is still controversial. Hence, we conducted this study to determine the potential correlation. Methods Eligible publications were searched in the Pubmed, Embase, and Cochrane Library through November 2016 according to the inclusion criteria and exclusion criteria. Revman 5.3 and Stata 12.0 software were used to analyze the relevant data regarding the association between the frequency of DAPK1 methylation and Gastrointestinal Cancer. Results A total of 22 studies with 2406 patients were included in this meta analysis. Methylation of DAPK1 was positively related with the risk of Gastrointestinal Cancer (odds ratio [OR] = 5.35, 95% confidence interval [CI]: 2.76–10.38, P
David A. August - One of the best experts on this subject based on the ideXlab platform.
-
Nutrition in Gastrointestinal Cancer
Clinical Gastroenterology, 1Co-Authors: Maureen B. Huhmann, David A. AugustAbstract:Gastrointestinal Cancers can significantly impact nutrition status. Data indicate that the presence of malnutrition in Cancer patients negatively impacts response to treatment, quality of life and survival. The nutritional support of patients with Gastrointestinal Cancer should be individualized and may be dependent upon antiCancer treatment modality. Interventions with parenteral nutrition, enteral nutrition and immunonutrition are indicated in certain situations. Nutritional modifications may also be important in the prevention of Cancer. This chapter will review some of the nutritional issues related to Gastrointestinal Cancer patients.
